Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets to support infrastructure development, research and the expansion of the latter’s biotech portfolio.
Swiss Rockets is the parent company of Rocketvax.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Alongside the investment, a strategic partnership is planned, positioning Emergent to spearhead the US manufacturing and commercialisation offerings for four of Rocketvax’s pipeline candidates targeting cancer, autoimmune disorders and infectious diseases.
One of these is a next-generation live-attenuated nasal spray SARS-CoV-2 vaccine. In animal studies, this vaccine has shown superior efficacy compared with messenger ribonucleic acid (mRNA) Covid-19 vaccines.
Rocketvax had previously initiated a partnership by signing a letter of intent with the US National Institutes of Health (NIH) under the Project NextGen initiative, facilitating a clinical trial to investigate a new vaccine leveraging the technology of Rocketvax.
Emergent provides health solutions for threats such as anthrax, botulism, Ebola, mpox, opioid overdose emergencies and smallpox.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRocketvax focuses on developing next-generation vaccines using molecular biology technologies based on live attenuated viruses.
Rocketvax CEO Dr Vladimir Cmiljanovic stated: “By partnering with Emergent BioSolutions, we are combining cutting-edge vaccine innovation with world-class production and regulatory expertise.
“This joint venture not only accelerates the development of next-generation vaccines but also paves the way for groundbreaking advancements in global healthcare. Our shared vision is to revolutionise disease prevention and immunotherapy, bringing life-saving solutions to millions worldwide.
“By joining forces with Emergent, we can leverage their world-class production capabilities to deliver next-generation vaccines that have the potential to transform disease prevention and immunotherapy.”
In August 2024, Emergent received US Food and Drug Administration (FDA) approval for its supplemental biologics licence application for ACAM2000, expanding its use to include the prevention of mpox.
